Yes, many patients without diabetes qualify for GLP-1 therapy based on BMI, insulin resistance, cardiovascular risk, or metabolic syndrome
(1) Dapagliflozin when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression
According to the study, the problem is actually even more serious, as L-carnitine also causes an increase in the bacteria that metabolises it, producing even greater amounts of the compound that causes arteriosclerosis trimethylamine N-oxide (known as TMAO)
van den Bos H, Spierings DC, Taudt AS, Bakker B, Porubsky D, Falconer E, et al
Raise a glass of kefir to your health and vitality today